Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

231 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
Nomiyama T, Shimono D, Horikawa T, Fujimura Y, Ohsako T, Terawaki Y, Fukuda T, Motonaga R, Tanabe M, Yanase T; Collaborators of Fukuoka Study of Ipragliflozin (FUSION) trial. Nomiyama T, et al. Endocr J. 2018 Aug 27;65(8):859-867. doi: 10.1507/endocrj.EJ18-0022. Epub 2018 May 26. Endocr J. 2018. PMID: 29806620 Free article. Clinical Trial.
SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation.
Komatsu S, Nomiyama T, Numata T, Kawanami T, Hamaguchi Y, Iwaya C, Horikawa T, Fujimura-Tanaka Y, Hamanoue N, Motonaga R, Tanabe M, Inoue R, Yanase T, Kawanami D. Komatsu S, et al. Among authors: nomiyama t. Endocr J. 2020 Jan 28;67(1):99-106. doi: 10.1507/endocrj.EJ19-0428. Epub 2019 Nov 27. Endocr J. 2020. PMID: 31776304 Free article.
Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F).
Terawaki Y, Iwaya C, Nomiyama T, Shimono D, Horikawa T, Fujimura-Tanaka Y, Shigeoka T, Hamanoue N, Motonaga R, Tanabe M, Yanase T, Kawanami D; Collaborators in the Repaglinide Glucose Oscillation Study in Fukuoka (REGO-F) trial. Terawaki Y, et al. Among authors: nomiyama t. Diabetol Int. 2020 Feb 14;11(3):274-282. doi: 10.1007/s13340-020-00426-w. eCollection 2020 Jul. Diabetol Int. 2020. PMID: 32802709 Free PMC article.
[Diabetes in other diseases and conditions].
Nomiyama T, Akehi Y, Yanase T. Nomiyama T, et al. Nihon Rinsho. 2012 May;70 Suppl 3:414-7. Nihon Rinsho. 2012. PMID: 22768556 Japanese. No abstract available.
231 results